Hypoxia induces different genes in the lungs of rats compared with mice

Physiological Genomics

Volumn 12, Issue , 2003, Pages 209-219

  Hoshikawa, Yasushi ^a,b   Nana Sinkam, Patrick ^a   Moore, Mark D ^a   Sotto Santiago, Sylk ^a   Phang, Tzulip ^a   Keith, Robert L ^a   Morris, Kenneth G ^a   Kondo, Takashi ^b   Tuder, Rubin M ^a   Voelkel, Norbert F ^a   Geraci, Mark W ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b TOHOKU UNIVERSITY   (Japan)

Author keywords

Chronic hypoxia; Gene microarray analysis; Pulmonary hypertension; Pulmonary vascular remodeling; Species differences

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD VESSEL TONE; CELL PROLIFERATION; CONTROLLED STUDY; DNA MICROARRAY; ENDOTHELIUM CELL; GENE CONTROL; GENE EXPRESSION; GENE INDUCTION; GENETIC ANALYSIS; HYPOXIA; LUNG PARENCHYMA; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; SPECIES DIFFERENCE; THICKNESS; UNINDEXED SEQUENCE; UPREGULATION; VASCULAR ENDOTHELIUM; VASODILATATION; ANIMAL; ANOXIA; C57BL MOUSE; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; GENETICS; LUNG; MALE; METABOLISM; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT;

ANIMALIA;

MESSENGER RNA; OSTEOPONTIN; SIALOGLYCOPROTEIN; SPP1 PROTEIN, MOUSE; SPP1 PROTEIN, RAT;

ANIMALS; ANOXIA; GENE EXPRESSION REGULATION; HYPERTENSION, PULMONARY; LUNG; MALE; MICE; MICE, INBRED C57BL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOPONTIN; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIALOGLYCOPROTEINS;

EID: 0141705757     PISSN: 15312267     EISSN: None     Source Type: Journal    
DOI: 10.1152/physiolgenomics.00081.2001     Document Type: Article

References (46)

1. Ambrosini G, Nath AK, Sierra-Honigmann MR, and Flores-Riveros J. Transcriptional activation of the human leptin gene in response to hypoxia. Involvement of hypoxia-inducible factor 1. J Biol Chem 277: 34601-34609, 2002.
2. Antonio V, Brouillet A, Janvier B, Monne C, Bereziat G, Andreani M, and Raymondjean M. Transcriptional regulation of the rat type IIA phospholipase A2 gene by cAMP and IL-1β in vascular smooth muscle cells: interplay of C/EBP, NF-κB, and Ets transcription factors. Biochem J 368: 415-424, 2002.
3. Arias-Stella J and Saldana M. Terminal portion of the pulmonary arterial in people native to high altitudes. Circulation 28: 915-925, 1963.
4. Bacqueville D, Casagrande F, Perret B, Chap H, Darbon JM, and Breton-Douillon M. Phosphatidylinositol 3-kinase inhibitors block aortic smooth muscle cell proliferation in mid-late G1 phase: effect on cyclin-dependent kinase 2 and the inhibitory protein p27KIP1. Biochem Biophys Res Commun 244: 630-636, 1998.
5. Benjamini Y and Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B57: 289-300, 1995.
6. Cao R, Brakenhielm E, Wahlestedt C, Thyberg J, and Cao Y. Leptin induces vascular permeability and synergistically stimulates angiogenesis with FGF-2 and VEGF. Proc Natl Acad Sci USA 98: 6390-6395, 2001.
7. Cowan KN, Jones PL, and Rabinovitch M. Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. J Clin Invest 105: 21-34, 2000.
8. Dempsey EC, Stenmark KR, McMurtry IF, O'Brien RF, Voelkel NF, and Badesch DB. Insulin-like growth factor I and protein kinase C activation stimulate pulmonary artery smooth muscle cell proliferation through separate but synergistic pathways. J Cell Physiol 144: 159-165, 1990.
9. Eddahibi S, Hanoun N, Lanfumey L, Lesch KP, Raffestin B, Hamon M, and Adnot S. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest 105: 1555-1562, 2000.
10. Eddahibi S, Humbert M, Fadel E, Raffestin B, Darmon M, Capron F, Simonneau G, Dartevelle P, Hamon M, and Adnot S. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 108: 1141-1150, 2001.
11. Eddahibi S, Raffestin B, Hamon M, and Adnot S. Is the serotonin transporter involved in the pathogenesis of pulmonary hypertension? J Lab Clin Med 139: 194-201, 2002.
12. Fagan KA, Fouty BW, Tyler RC, Morris KG Jr, Hepler LK, Sato K, Le Cras TD, Abman SH, Weinberger HD, Huang PL, McMurtry IF, and Rodman DM. The pulmonary circulation of homozygous or heterozygous eNOS-null mice is hyperresponsive to mild hypoxia. J Clin Invest 103: 291-299, 1999.
13. Geraci MW, Gao B, Shepherd DC, Moore MD, Westcott JY, Fagan KA, Alger LA, Tuder RM, and Voelkel NF. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J Clin Invest 103: 1509-1515, 1999.
14. Geraci MW, Moore M, Gesell T, Yeager ME, Alger L, Golpon H, Gao B, Loyd JE, Tuder RM, and Voelkel NF. Gene expression patterns in the lungs of patients with primary pulmonary hypertension: a gene microarray analysis. Circ Res 88: 555-562, 2001.
15. Golpon HA, Geraci MW, Moore MD, Miller HL, Miller GJ, Tuder RM, and Voelkel NF. HOX genes in human lung: altered expression in primary pulmonary hypertension and emphysema. Am J Pathol 158: 955-966, 2001.
16. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, and Lander ES. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286: 531-537, 1999.
17. Grover RF, Reeves JT, Weir EK, McMurtry IF, and Alexander AF. Genetic transmission of susceptibility to hypoxic pulmonary hypertension. Prog Respir Res 9: 112-117, 1975.
18. Grover RF, Vogel JK, Averill KH, and Blount SG. Pulmonary hypertension: individual and species variability relative to vascular reactivity. Am Heart J 66: 1-3, 1963.
19. Hales CA, Kradin RL, Brandstetter RD, and Zhu YJ. Impairment of hypoxic pulmonary artery remodeling by heparin in mice. Am Rev Respir Dis 128: 747-751, 1983.
20. Hanson WL, Boggs DF, Kay JM, Hofmeister SE, Okada O, and Wagner WW Jr. Pulmonary vascular response of the coati to chronic hypoxia. J Appl Physiol 88: 981-986, 2000.
21. Hanson WL, Boggs DF, Kay JM, Hofmeister SE, and Wagner WW Jr. Collateral ventilation and pulmonary arterial smooth muscle in the coati. J Appl Physiol 74: 2219-2224, 1993.
22. Hogg RV and Craig AT. Introduction to Mathematical Statistics. Upper Saddle River, NJ: Prentice Hall, 1995.
23. Hoshikawa Y, Ono S, Suzuki S, Tanita T, Chida M, Song C, Noda M, Tabata T, Voelkel NF, and Fujimura S. Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia. J Appl Physiol 90: 1299-1306, 2001.
24. Hoshikawa Y, Voelkel NF, Gesell TL, Moore MD, Morris KG, Alger LA, Narumiya S, and Geraci MW. Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling. Am J Respir Crit Care Med 164: 314-318, 2001.
25. Jones PL, Chapados R, Baldwin HS, Raff GW, Vitvitsky EV, Spray TL, and Gaynor JW. Altered hemodynamics controls matrix metalloproteinase activity and tenascin-C expression in neonatal pig lung. Am J Physiol Lung Cell Mol Physiol 282: L26-L35, 2002.
26. Kanzaki T, Shiina R, Saito Y, Oohashi H, and Morisaki N. Role of latent TGF-β1 binding protein in vascular remodeling. Biochem Biophys Res Commun 246: 26-30, 1998.
27. Le Cras TD, Xue C, Rengasamy A, and Johns RA. Chronic hypoxia upregulates endothelial and inducible NO synthase gene and protein expression in rat lung. Am J Physiol Lung Cell Mol Physiol 270: L164-L170, 1996.
28. Lee CK, Klopp RG, Weindruch R, and Prolla TA. Gene expression profile of aging and its retardation by caloric restriction. Science 285: 1390-1393, 1999.
29. Li H, Chen SJ, Chen YF, Meng QC, Durand J, Oparil S, and Elton TS. Enhanced endothelin-1 and endothelin receptor gene expression in chronic hypoxia. J Appl Physiol 77: 1451-1459, 1994.
30. Liu G, Eskin SG, and Mikos AG. Integrin αvβ3 is involved in stimulated migration of vascular adventitial fibroblasts by basic fibroblast growth factor but not platelet-derived growth factor. J Cell Biochem 83: 129-135, 2001.
31. Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS, Mittmann M, Wang C, Kobayashi M, Horton H, and Brown EL. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 14: 1675-1680, 1996.
32. Rabinovitch M, Gamble W, Nadas AS, Miettinen OS, and Reid L. Rat pulmonary circulation after chronic hypoxia: hemodynamic and structural features. Am J Physiol Heart Circ Physiol 236: H818-H827, 1979.
33. Semenza GL. Surviving ischemia: adaptive responses mediated by hypoxia-inducible factor 1. J Clin Invest 106: 809-812, 2000.
34. Sugita M, Geraci M, Gao B, Powell RL, Hirsch FR, Johnson G, Lapadat R, Gabrielson E, Bremnes R, Bunn PA, and Franklin WA. Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma. Cancer Res 62: 3971-3979, 2002.
35. Thompson K and Rabinovitch M. Exogenous leukocyte and endogenous elastases can mediate mitogenic activity in pulmonary artery smooth muscle cells by release of extracellular-matrix bound basic fibroblast growth factor. J Cell Physiol 166: 495-505, 1996.
36. Tucker A, McMurtry IF, Reeves JT, Alexander AF, Will DH, and Grover RF. Lung vascular smooth muscle as a determinant of pulmonary hypertension at high altitude. Am J Physiol 228: 762-767, 1975.
37. Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, Badesch D, and Voelkel NF. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 159: 1925-1932, 1999.
38. Tuder RM, Groves B, Badesch DB, and Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 144: 275-285, 1994.
39. Voelkel NF, Allard JD, Anderson SM, and Burke TJ. cGMP and cAMP cause pulmonary vasoconstriction in the presence of hemolysate. J Appl Physiol 86: 1715-1720, 1999.
40. Voelkel NF and Tuder RM. Hypoxia-induced pulmonary vascular remodeling: a model for what human disease? J Clin Invest 106: 733-738, 2000.
41. Voelkel NF, Tuder RM, Bridges J, and Arend WP. Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline. Am J Respir Cell Mol Biol 11: 664-675, 1994.
42. Voelkel NF, Tuder RM, Wade K, Hoper M, Lepley RA, Goulet JL, Koller BH, and Fitzpatrick F. Inhibition of 5-lipoxygenase-activating protein (FLAP) reduces pulmonary vascular reactivity and pulmonary hypertension in hypoxic rats. J Clin Invest 97: 2491-2498, 1996.
43. Walker BR, Berend N, and Voelkel NF. Comparison of muscular pulmonary arteries in low and high altitude hamsters and rats. Respir Physiol 56: 45-50, 1984.
44. Will DH, Alexader AF, Reeves JT, and Grover RF. High altitude-induced pulmonary hypertension in normal cattle. Circ Res 10: 172-177, 1962.
45. Yamamoto M, Aoyagi M, Azuma H, and Yamamoto K. Changes in osteopontin mRNA expression during phenotypic transition of rabbit arterial smooth muscle cells. Histochem Cell Biol 107: 279-287, 1997.
46. Yan SF, Fujita T, Lu J, Okada K, Shan ZY, Mackman N, Pinsky DJ, and Stern DM. Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. Nat Med 6: 1355-1361, 2000.